Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Erlotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 17/20 | 0.73 |
| ▸ | FBP1 | P09467 | 2/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.73 |
| ▸ | GAK | O14976 | 3/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.73 |
| ▸ | BUB1 | O43683 | 2/20 | 0.73 |
| ▸ | STK10 | O94804 | 2/20 | 0.73 |
| ▸ | ABL1 | P00519 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 2/20 | 0.73 |
| ▸ | LYN | P07948 | 2/20 | 0.73 |
| ▸ | RET | P07949 | 2/20 | 0.73 |
| ▸ | SRC | P12931 | 2/20 | 0.73 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.73 |
| ▸ | FECH | P22830 | 2/20 | 0.73 |
| ▸ | KDR | P35968 | 2/20 | 0.73 |
| ▸ | FLT3 | P36888 | 2/20 | 0.73 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.73 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.73 |
| ▸ | ILK | Q13418 | 2/20 | 0.73 |
| ▸ | PLK4 | O00444 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erlotinib SCHEMBL13087124 | 0.93 | EGFR (0.78) | FBP1EGFRERBB2GAKRIPK2 | |
| Erlotinib SCHEMBL29608228 | 0.90 | EGFR (0.86) | FBP1EGFRERBB2GAKRIPK2 | |
| Erlotinib SCHEMBL13087052 | 0.90 | EGFR (0.86) | FBP1EGFRERBB2GAKRIPK2 | |
| Erlotinib SCHEMBL3057695 | 0.89 | EGFR (0.87) | FBP1EGFRERBB2GAKRIPK2 | |
| Erlotinib SCHEMBL13087138 | 0.87 | EGFR (0.85) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL2129772 | 0.87 | EGFR (0.84) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL2464248 | 0.85 | EGFR (0.82) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL4123388 | 0.85 | FBP1 (1.00) | FBP1EGFRERBB2GAKRIPK2 | |
| Erlotinib SCHEMBL30362833 | 0.85 | EGFR (1.00) | FBP1EGFRERBB2GAKRIPK2 | |
| Erlotinib SCHEMBL3667407 | 0.85 | EGFR (1.00) | FBP1EGFRERBB2GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | EGFR 19/4885FBP1 3745/4885ERBB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.